Levofloxacin hemihydrate

Levofloxacin hydrate (CAS No.: 138199-71-0) serves as a potent agent within the realm of biomedical research and drug discovery, renowned for its classification as a broad-spectrum, third-generation fluoroquinolone antibiotic. As the optically active L-isomer of ofloxacin, it exhibits significant antibacterial activity, primarily through its inhibition of bacterial enzymes DNA gyrase and topoisomerase IV, which are crucial for DNA replication, RNA transcription, and the repair of bacterial DNA. Its mechanism disrupts bacterial cell growth, making it effective against both Gram-positive and Gram-negative bacteria. Research applications extensively utilize this compound in studies of chronic periodontitis, airway inflammation, and BK viral infections. Furthermore, levofloxacin hydrate is highlighted for its anti-poxvirus activity, providing a broad scope for investigating viral mechanisms and interactions. Experimental activities generally fall within the nanomolar to micromolar range, though precise data requires context-specific experimental setups. Its use in various in vitro and in vivo models aids in validating pharmacokinetic and pharmacodynamic properties crucial for drug screening processes. Concentrations or doses in research are tailored based on the specific design and objectives of the studies, ensuring versatility across a wide array of biomedical investigations.